New hope for advanced liver cancer: drug combo trial opens
NCT ID NCT05257590
First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests a new experimental drug called CVM-1118 combined with the immunotherapy nivolumab in people with advanced liver cancer that cannot be surgically removed. The goal is to see if the combination shrinks tumors or slows cancer growth. About 95 adults aged 18 and older (20+ in Taiwan) with confirmed hepatocellular carcinoma are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Chang Gung Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
Contact
-
Keelung Chang Gung Memorial Hospital
RECRUITINGKeelung, Taiwan
Contact
-
National Cheng Kung University Hospital
RECRUITINGTainan, Taiwan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, 100, Taiwan
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 112, Taiwan
Contact
Conditions
Explore the condition pages connected to this study.